JAK1 inhibitor induces clinical response in UC

JAK1 inhibitor induces clinical response in UC

Selective janus kinase 1 inhibitor, SHR0302, induced clinical response and remission among patients with moderate to severe ulcerative colitis, according to a study at Digestive Disease Week.“JAK signaling plays an important role in the pathogenesis of UC by blocking the JAK-STAT pathway,” Min-Hu Chen, MD, PhD, The First Affiliated Hospital, Sun Yat-sen University, said. “SHR0302 is a selective JAK1 inhibitor currently under clinical development for the treatment of UC, rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, Crohn’s disease and alopecia areata.”Read More

Share on facebook
Share on twitter
Share on linkedin